Comparison of the therapeutic efficacy of oral doses of fluconazole and itraconazole in a guinea pig model of dermatophytosis

Journal of Infection and Chemotherapy

Volumn 6, Issue 1, 2000, Pages 41-44

  Nagino, Kenji ^a   Shimohira, Hiroshi ^a   Ogawa, Masatoshi ^a   Uchida, Katsuhisa ^b   Yamaguchi, Hideyo ^b  

^a PFIZER INC   (United States)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Fluconazole; Guinea pig dermatophytosis; Itraconazole; Oral therapy; Trichophyton mentagrophytes infection

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMATOMYCOSIS; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GUINEA PIG; NONHUMAN; SKIN INFECTION; TRICHOPHYTON MENTAGROPHYTES;

EID: 0034015587     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560050048     Document Type: Article

References (29)

1. Degreef HJ, DeDoncker PR. Current therapy of dermatophytosis. J Am Acad Dermatol 1994;31:S25-30.
2. Lesher JL Jr. Recent developments in antifungal therapy. Dermatol Clin 1996;14:163-9.
3. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
4. Yamaguchi H, Uchida K, Kawasaki K, Matsunaga T. In vitro activity of fluconazole, a novel bistriazole antifungal agent. Jpn J Antibiotics 1989;42:1-16.
5. De Bersaques J, Bjerke JR, Borelli S, Brown AC, Cottenot F, Daniel F, et al. Comparison of oral fluconazole and topical clotrimazole in the treatment of fungal infections of the skin: European and American experience. Int J Dermatol 1992;31(Suppl 2):21-6.
6. De Cuyper C, De Bersaques J, Delescluse J, Grigoriu D, Haneke E, Hay RJ, et al. Evaluation of four oral daily doses of fluconazole in the treatment of cutaneous mycoses. Int J Dermatol 1992; 31(Suppl 2):8-11.
7. Fischbein A, Haneke E, Lancer K, Male O, Mohn R, Muller H, et al. Comparative evaluation of oral fluconazole and oral ketoconazole in the treatment of fungal infections of the skin. Int J Dermatol 1992;31 (Suppl 2):12-6.
8. Yoshida T, Uchida K, Yamaguchi H. An ATP bioluminesence assay applicable to rapid fluconazole susceptibility testing of dermatophytes. Microbiol Immunol 1997;41:377-96.
9. Ohmi T, Konaka S, Uchida M, Yamaguchi H. Antifungal activity of a new agent latoconazole in two tinea models. Arzneim-Forsch/ Drug Res 1991;41:847-51.
10. Uchida K, Yamaguchi H, Shibuya K. The therapeutic effects of itraconazole, a new triazole antifungal agent, for experimental fungal infections. Jpn J Antibiotics 1991;44:588-99.
11. Uchida K, Yamaguchi H. Therapeutic efficacy of oral administration of terbinafine in guinea pig trichophytosis model. Jpn J Med Mycol 1993;34:485-91.
12. Van Eldere J, Joosten L, Verhaeghe V, Surmont I. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. J Clin Microbiol 1996;34:842-7.
13. Barchiesi F, Colombo AL, McGough DA, Rinaldi MG. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol 1994;32:2494-500.
14. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53.
15. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1985;32:1-8.
16. Troke PF, Andrews RJ, Brammer KW, Marriott MS, Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother 1985;28:815-8.
17. Rogers TE, Galgiani JN. Activity of fluconazole (UK-49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1986;30:418-22.
18. Van't Wout JW, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother 1989;33:147-51.
19. Palou de Fernandez E, Patino MM, Graybill JR, Tarbit MH. Treatment of cryptococcal meningitis in mice with fluconazole. J Antimicrob Chemother 1986;18:261-70.
20. Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob Agents Chemother 1986;29:579-83.
21. Richardson K, Brammer KW, Marriott MS, Troke PF. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 1985;27:832-5.
22. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996;5:585-620.
23. Espinel-Ingroff A, Dawson K, Pfaller M, Anaissie E, Breslin B, Dixon D, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39:314-9.
24. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993;18:102-6.
25. Hay RJ. Pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol 1992;31 (Suppl 2):6-7.
26. Wildfeuer A, Faergemann J, Laufen H, Pfaff G, Zimmermann T, Seidl HP, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994;37:127-30.
27. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53.
28. Van Cauteren H, Heykants J, De Coster R, Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis 1987;9(Suppl 1):S43-6.
29. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18:263-8.